Drug Profile
Edicotinib - Janssen Research & Development
Alternative Names: Edicotinib hydrochloride; JNJ-244; JNJ-40346527; JNJ-40346527-AAC-G-002; JNJ-527; PRV 6527Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development; OHSU Knight Cancer Institute; Oregon Health & Science University; Provention Bio; The Leukemia & Lymphoma Society
- Class Anti-inflammatories; Antidementias; Antineoplastics; Antirheumatics; Cyclohexanes; Imidazoles; Small molecules
- Mechanism of Action Macrophage colony stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cognition disorders; Crohn's disease
- No development reported Acute myeloid leukaemia; Adenocarcinoma
- Discontinued Hodgkin's disease; Inflammation; Rheumatoid arthritis
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Adenocarcinoma(First-line therapy, Late-stage disease) in USA (PO)
- 30 Jan 2024 M.D. Anderson Cancer Center completes a phase I trial in Adenocarcinoma (First-line therapy, Late-stage disease) in USA (IV) (NCT03177460)
- 27 Apr 2023 Provention Bio has been acquired by Sanofi